Exozymes Inc. · NASDAQ:EXOZ
Exozymes — Investor Presentation (August 2025)
42 slides from Exozymes's investor presentation, August 2025
Slide 1: The Next Generation of Biomanufacturing
The Next Generation of Biomanufacturing Michael Heltzen, CEO
Slide 2: eXoZymes' Safe Harbor
eXoZymes’ Safe Harbor This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, which are based on certain assumptions and describe the company’s future plans, strategies and expectations, can general
Slide 3: eXoZymes' vision
eXoZymes’ vision Solving a generational problem A lack of sustainable access to chemicals, which form the basis of modern life
Slide 4: enzymes = AI = eXoZymes
enzymes = Al = eXOzymes
Slide 5: Resources via conventional methods
Resources via conventional methods Plant-derived Petroleum-based Cell-based chemicals chemicals synthetic biology
Slide 6: Problems with conventional methods
Problems with conventional methods Plant-derived Petroleum-based Cell-based chemicals chemicals synthetic biology Depleting natural Polluting Rarely makes it to resources and toxic commercial scale
Slide 7: Old SynBio paradigm: How cells makes chemicals
Old SynBio paradigm: How cells makes chemicals Sugar/Feedstock Cell
Slide 8: Top reasons why SynBio/cells/fermentation is not ideal
Top reasons why SynBio/cells/fermentation is not ideal 1 2 3 Cells are, by evolution, The cells often get sick Most SynBio projects designed to only do things or die from the toxic commercially die as that help the cell survive, chemicals or the the isolation cost to get grow, and replicate. They in
Slide 9: How are exozymes different to synthetic biology?
How are exozymes different to synthetic biology?
Slide 10: Old SynBio paradigm: How cells makes chemicals
Old SynBio paradigm: How cells makes chemicals Why not just liberate the Sugar/Feedstock Cell Enzymatic Pathway from the cell? Former belief system: Enzyme Pathways does not function outside of cells…
Slide 11: Cell-based enzymes vs exozyme biosolutions
Cell-based enzymes vs exozyme biosolutions cell-based synbio exozyme biosolutions = exozymes (AI-optimized enzymes) + production pathways helper modules Sugar/Feedstock Biomass/Sugar/ Cell-free Exozyme Pathway Chemistry Feedstock & Support Modules Product • Engineering-level control • Efficient use
Slide 12: enzymes = AI = eXoZymes
enzymes = Al = eXOzymes
Slide 13: Proprietary enzyme knowledge and technology
* * Proprietary enzyme knowledge and technology – both wet-lab and dry-lab. - e.g. one of our secret sauces is how we generate enzyme training data.
Slide 14: The market leader of cell-free exozymes biomanufacturing
The market leader of cell-free exozymes biomanufacturing
Slide 15: Exozymes is the next gen of biomanufacturing
cell-based SynBio was the last generation exozymes is the next gen of biomanufacturing.
Slide 16: exozymes.com/exoz
eX0Zy mes ee ay mie se Pehl baa
Slide 17: Nutraceuticals with a pharmaceutical potential
Nutraceuticals with a pharmaceutical potential
Slide 18: An exozymes biosolution for NCT
An exozymes biosolution for NCT www.NCTx.one
Slide 19: N-trans-Caffeoyltyramine (NCT): A Nutraceutical with Pharmaceutical Potential
An exozyme biosolution for N-trans-Caffeoyltyramine – aka NCT A Nutraceutical with Pharmaceutical Potential A potent HNF4a agonist, and candidate for fatty liver disease and gut health www.NCTx.one CAS: 103188-48-3 Purity: >98%
Slide 20: When NCT meets the HNF4a drug receptor it becomes a potent agonist
When NCT meets the HNF4a drug receptor it becomes a potent agonist Agonist: A small molecule that, upon binding to a receptor, activates it and produces a biological response.
Slide 21: The leading pre-clinical model experts in the world, say…
The leading pre-clinical model experts in the world, say… “NCT was completely nontoxic at the highest dose administered and so is a strong candidate for an NAFLD (fatty liver disease) therapeutic.” “These (studies and) data suggest that HNF4a could be a therapeutic target for Inflammatory bowel dise
Slide 22: What is Non-Alcoholic Fatty Liver Disease (NAFLD)?
What is Non-Alcoholic Fatty Liver Disease (NAFLD)? Size of problem • Globally impacts over 30% of adults and growing fast • Closely linked to obesity, gut health, maybe diabetes • Very few good medical options • A huge problem for the individual and society
Slide 23: NCT - The first of many natural products and analogs
NCT - The first of many natural products and new-to-nature analogs that can now be biomanufactured
Slide 24: As well as extraordinary business opportunities
As well as extraordinary business opportunities
Slide 25: As well as extraordinary business opportunities
As well as extraordinary business opportunities Customer(s) via grants: DoD & DoE Aviation Fuel Market: $793B Isobutanol used as Sustainable Aviation Fuel (SAF) • A liquid fuel already used in commercial aviation, $220B which reduces CO2 emissions by up to 80% • A politically mandated hyper-growth m
Slide 26: Approx $14MM in US Gov grants enabling cell free platform
Approx $14MM in US Gov grants enabling the development of our cell free platform technology Cannabinoids Cofactors Proteins $150k Phase II SBIR $2.3MM $150k Phase I SBIR TCF Cannabinoids Isobutanol $2.1MM Cell-Free $2MM BETO Subcontract $50k Phase II SBIR $3.7MM Methylation Alcohols $245k ARPAe $1.6
Slide 27: Background
Background Location: Pasadena, CA. 30 full-time, and a very large support system. 2019: UCLA spin-out, “Big Idea” status = MDB Capital backed. 2020/22: POC projects and technology platform development. 2023: AI/ML and state-of-the-art enzyme engineering capabilities. 2024: Commercial CEO, focus stra
Slide 28: Management team
Damien Paul Tyler Michael Fouad Zachary Lasse H. Perriman Opgenorth, PhD Korman, PhD Heltzen Nawaz Karl, PhD Görlitz CCO VP of Development VP of Research CEO VP of Finance VP of Business Development VP of Comms
Slide 29: eXoZymes Inc. a platform-of-platforms company
eXoZymes Inc. a platform-of-platforms company short term: kick-starting tech use via spin-outs and JVs, longer term: mostly sell and license exozymes technology
Slide 30: The future is bright
The future is brighit
Slide 31: If you want to learn more as an investor
If you want to learn more as an investor www.exozymes.com/exoz
Slide 32: Thank you for your attention and participation!
Thank you for your attention and participation!
Slide 33: Questions
Questions
Slide 34: Financials
Financials Please see exozymes.com/sec-filings for details
Slide 35: Recognized leader of cell-free biomanufacturing in peer-reviewed journals
Recognized leader of cell-free biomanufacturing in peer-reviewed scientific journals 3x published Cover story 4x published
Slide 36: eXoZymes R&D de-risking and speed-up process
eXoZymes R&D de-risking and speed-up process STEP 1 STEP 2 STEP 3 STEP 4 PRODUCT SELECTION DESIGN PATHWAYS BUILD LAB ENZYME DEVELOP PILOT TO TARGET SCALE WORKING OPTIMIZATION SCALE COMMERCIALIZATION CHEMICAL PROTOTYPE PRODUCTION PARTNER & FUNDING Developing cell-free biomanufacturing solutions ready
Slide 37: Business model leverages IP for proprietary processes, key enzymes, and novel chemicals
Business model leverages IP for proprietary processes, key enzymes, and novel chemicals 10+ patents and substantial trade secrets protecting Patents & Novel cell-free Advanced AI & Novel Enzymes Novel & rare trade secrets biomanufacturing R&D platform & exozymes chemicals
Slide 38: Focus on opportunities and markets that create value for shareholders
Focus on opportunities and markets that create value for our shareholders High Value, High Value, Clear Path to Market Difficult Path to Market Potential Value Creation Low Value, Low Value, Clear Path to Market Difficult Path to Market Difficulty of Commercialization
Slide 39: Partnership deal funnel optimization
Partnership deal funnel optimization 1. Initial Discussions 2. Technical Alignment Key Considerations • Discernment in deal selection 3. Deal Terms • Balanced funnel dynamics Discussion • Continuous replenishment 4. Term Sheet • Efficient transition and progression 7. Nurture 5. Definitive • Quality
Slide 40: Next generation biomanufacturing for drug discovery and development
Next generation biomanufacturing for drug discovery and development • Enables new and better drugs otherwise impossible to make • Allows for the biochemical engineering and mass production of a new generation of complex drug molecules, by overcoming the limitations of cellular metabolism and first-g
Slide 41: Isobutanol used as Sustainable Aviation Fuel (SAF)
Isobutanol used as Sustainable Aviation Fuel (SAF) • A liquid fuel already used in commercial aviation, which reduces CO2 emissions by up to 80% Total Addressable Market (US) • Comprises less than 0.1% of aviation fuels, but all airlines are looking for suppliers $793B • Healthy premiums/subsidies p
Slide 42: Business model with asymmetric upside potential
Business model with assymetric upside potential Limited Unlimited High Impact Downside Upside on NPV • Foundational • Unlimited markets • Ability to disrupt multiple, patents multi-billion-dollar markets • Multiple revenue • Capital light streams : • Value creation potential significant without the